Drug
Belumosudil (KD025)
Belumosudil (KD025) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
300%(3 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
terminated267%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_2
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
NCT03640481
terminatedphase_2
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
NCT03919799
completedphase_2
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
NCT02841995
Clinical Trials (3)
Showing 3 of 3 trials
NCT03640481Phase 2
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
NCT03919799Phase 2
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
NCT02841995Phase 2
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3